Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2025-12-18 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
北京市康达律师事务所关于拓新药业集团股份有限公司2025年第三次临时股东会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, voting procedures, and results of the 2025 third extraordinary shareholders' meeting of a company. It details the legal compliance of the meeting process, the qualifications of attendees, and the voting outcomes on various proposals. The document does not contain financial statements or management discussion of financial results but focuses on the legality and validity of the shareholders' meeting and its resolutions. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, rather than a financial report or announcement of voting results alone. Therefore, it fits best under the category of Legal Proceedings Report (LTR).
2025-12-18 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the principles, structure, and procedures for determining and managing the compensation of the company's directors and senior executives. It references relevant laws and company bylaws, outlines the roles of the remuneration committee, and describes the components of remuneration including base salary, performance pay, and long-term incentives. There is no financial data or report content, but rather a policy document on remuneration. This matches the definition of a Remuneration Information filing, which reports on compensation for top executives and directors.
2025-12-02 Chinese
关于预计2026年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the year 2026 by the company 拓新药业集团股份有限公司. It details the nature, amounts, and rationale for these transactions, including independent directors' opinions and board meeting resolutions. The document is a formal disclosure of anticipated related party dealings, not a financial report or audit. It does not contain financial statements or detailed financial analysis but rather informs shareholders and the market about expected related party transactions and compliance with regulations. This fits the profile of a Regulatory Filing (RNS) as it is a regulatory announcement about related party transactions without being a full report or financial statement.
2025-12-02 Chinese
关于召开2025年第三次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2025 third extraordinary general meeting of shareholders for the company 拓新药业集团股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), registration details, agenda items to be voted on, and attachments such as proxy forms and voting instructions. There is no financial data or report content; rather, it is an announcement and procedural guide for the shareholders' meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document length is about 4717 characters, which is consistent with a detailed meeting notice rather than a full report or voting results announcement.
2025-12-02 Chinese
关于公司及子公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's and its subsidiaries' application for a comprehensive credit facility from banks. It details the board meeting resolution approving the credit limit and explains the purpose and impact of the financing. There are no financial statements or detailed financial data presented, nor is this a full report or earnings release. The document is a financing update related to capital structure and funding activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not merely announcing the publication of a report, so it is not RPA or RNS.
2025-12-02 Chinese
关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (信永中和会计师事务所) for auditing the company's 2026 financial reports and internal controls. It details the firm's qualifications, personnel, audit fees, and the approval process by the board and audit committee. The document does not contain actual financial statements or audit results but is a formal notice about the engagement of the auditor for the upcoming fiscal year. It is not an audit report itself, nor an annual or interim report. Given the nature of the content as an announcement about auditor reappointment, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not fit other specific categories.
2025-12-02 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.